Free Trial
NASDAQ:QNRX

Quoin Pharmaceuticals Q1 2025 Earnings Report

Quoin Pharmaceuticals logo
$5.00 +0.16 (+3.31%)
Closing price 04:00 PM Eastern
Extended Trading
$5.04 +0.04 (+0.90%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quoin Pharmaceuticals EPS Results

Actual EPS
-$6.50
Consensus EPS
-$3.85
Beat/Miss
Missed by -$2.65
One Year Ago EPS
N/A

Quoin Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quoin Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Quoin Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Quoin Pharmaceuticals Earnings Headlines

Quoin Pharmaceuticals. Ltd Sponsored ADR
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…tc pixel
See More Quoin Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ:QNRX), Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

View Quoin Pharmaceuticals Profile